[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT01874093 : IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset|
|Ages||Min: 40 Years Max: 85 Years|
1. Age: ? 40 years and ? 80 years for male and 85 for female subjects
2. Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior
Cerebral Artery territories based on general physical examination and neurological
3. Imaging findings demonstrating signs of ischemia (or total arterial occlusion prior to
the MT procedure) in the anterior circulation, consistent with the clinical diagnosis.
4. Performance of MT within <8 hours from stroke onset and/or administration of IV-rtPA
within ? 4.5 hours from stroke onset.
5. NIHSS ? 7 and ? 18 within 2 hours prior to implantation.
6. Ability to initiate treatment within
? 24 hours from stroke onset.
7. Signed informed consent from patient him/herself or legally authorized representative
1. Neuro-imaging evidence of any intracranial hemorrhage (including suspect of Sub
Arachnoid Hemorrhage) or hemorrhagic transformation of brain infarct or other
significant abnormality (e.g. tumor, abscess)
2. Massive stroke, defined as acute parenchymal lesion with effacement of cerebral sulci
in over 2/3 of the MCA territory.
3. Acute stroke due to lacunar infarct as defined by a clinical syndrome (pure motor
hemiparesis, ataxic hemiparesis, sensorimotor stroke, dysarthria-clumsy hand
syndrome), unless brain imaging demonstrates a relevant lesion > 1.5 cm in size.
4. Clinical signs and symptoms or evidence for a relevant lesion by neuro-imaging of an
acute ischemic stroke in the posterior circulation (Vertebral, Basilar and/or
Posterior Cerebral Artery territories), including but not limited to brain-stem
findings and/or cerebellar findings and/or isolated homonymous hemianopia or cortical
5. Minor stroke with non-disabling deficit or rapidly improving neurological symptoms.
6. Clinical signs and symptoms or imaging evidence of bilateral stroke.
7. Treated with IA-rtPA for the current stroke.
8. Complicated MT procedure (including procedures with more than 3 clot removal attempts
(catheter passes), or MT procedure that lasted more than 2 hours)
9. NIHSS level of consciousness score ? 2.
10. Previous stroke in the last 6 months or previous stroke with existing sequelae or with
mRS > 0 for any reason
11. Pre-existing disability; Pre-existing Modified Rankin Score >1, even if not
12. Patients with bleeding propensity and/or one of the following: INR? 1.8, prolonged
activated partial thromboplastin time (aPTT) ? 45 sec., platelets count < 75×109/L
prior to the implantation/sham procedure.
13. Known cerebral arteriovenous malformation, cerebral aneurysm.
14. Seizure at onset.
15. Blood glucose concentration < 60 mg/dL.
16. Clinical suspicion of septic embolus.
17. Uncontrolled hypertension (systolic >185 mmHg and/or diastolic >110 mmHg),
demonstrated on each of three repeated measurements taken within one hour regardless
of whether or not the patient is taking antihypertensive medications.
18. Serious systemic infection.
19. Women known to be pregnant or having a positive or indeterminate pregnancy test.
20. Patients with other implanted neural stimulator/ electronic devices (pacemakers,
21. History of SPG ablation ipsilateral to the stroke side.
22. Any condition in the oral cavity that prevents implantation of the INS, such as
patient is intubated, orthodontics or non-hygienic condition.
23. Life expectancy < 1 year from causes other than stroke.
24. Participating in any other therapeutic investigational trial within the last 30 days.
25. Known sensitivity to any medication to be used during study.
26. Subjects who have a clinically significant or unstable medical or surgical condition
that may preclude safe and complete study participation. Conditions may include:
cardiovascular, vascular, pulmonary, hepatic, renal or neurological (other than acute
ischemic stroke), or neoplastic diseases, as determined by medical history, physical
examination, laboratory tests, or ECG.
27. Subjects who, in the judgment of the investigator, are likely to be non-compliant or
uncooperative during the study.
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01874093
| Link to official Clinicaltrials.gov listing